As of Dec. 29, the FDA has placed every product featuring the transmucosal delivery of fentanyl under a single Risk Evaluation and Mitigation Strategy, also known as REMS. Fentanyl is used to treat cancer-related pain when other medicines don't work. A REMS program guides how a drug is made available to patients to protect their health and limit drug abuse. The decision is expected to help companies such as BioDelivery Sciences International ($BDSI), which makes a product that delivers fentanyl through a film placed on the inside of the cheek, reports MedCityNews.com. Story